Cancer Immunology Research

Cancer Immunol Res. 2025 Mar 14:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-0202. Online ahead of print. ABSTRACT Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, … Read more

Cancer Immunol Res. 2025 Mar 14:OF1-OF20. doi: 10.1158/2326-6066.CIR-24-0151. Online ahead of print. ABSTRACT Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling the complex network of immune cells within the tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many … Read more

Cancer Immunol Res. 2025 Mar 12. doi: 10.1158/2326-6066.CIR-24-0758. Online ahead of print. ABSTRACT Agonistic anti-CD40 with anti-PD-1 can elicit objective responses in a small number of patients with pancreatic ductal adenocarcinoma (PDA). Better understanding of their individual effects on the PDA tumor microenvironment will help inform new strategies to further improve outcomes. Herein, we map … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0379. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) has revolutionized the therapeutic landscape across various cancer types. However, the emergence of resistance to ICB therapy limits its clinical application. Therefore, it is necessary to better understand immune-resistance mechanisms that could be targeted by actionable drugs, and … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0804. Online ahead of print. ABSTRACT mRNA vaccines are recognized as potent tools for immunization against viral diseases and cancer. However, the lack of a vaccine adjuvant limits the efficacy of these treatments. Here, we used cGAS mRNA, which encodes the DNA innate immune sensor, complexed with lipid … Read more

Cancer Immunol Res. 2025 Mar 11. doi: 10.1158/2326-6066.CIR-24-0263. Online ahead of print. ABSTRACT Cytotoxic chemotherapy that kills cancer cells can also elicit anti-tumor immune responses. Therefore, understanding the immunogenic context of cytotoxic chemotherapy can improve combination immunotherapies. In this study, we sought to improve our understanding about dendritic cell (DC) dynamics in cytotoxic chemotherapy-treated tumor … Read more

Cancer Immunol Res. 2025 Mar 4;13(3):309. doi: 10.1158/2326-6066.CIR-13-3-WWR. NO ABSTRACT PMID:40033981 | DOI:10.1158/2326-6066.CIR-13-3-WWR

Cancer Immunol Res. 2025 Feb 26. doi: 10.1158/2326-6066.CIR-24-1094. Online ahead of print. ABSTRACT Denosumab, a RANKL inhibitor, is primarily used to prevent osteoclastogenesis in the treatment of conditions such as osteoporosis, bone metastasis, and giant cell tumour of bone (GCTB). RANKL also plays an important role in immunity by activating NF-κB and its target genes, … Read more

Cancer Immunol Res. 2025 Feb 25:OF1-OF7. doi: 10.1158/2326-6066.CIR-24-1046. Online ahead of print. ABSTRACT The advent of syngeneic mouse tumor models provided the scientific foundation for cancer immunotherapies now in widespread use. However, in many respects, these models do not faithfully recapitulate the interactions between cancer cells and the immune systems of human patients who have … Read more

Cancer Immunol Res. 2025 Feb 21. doi: 10.1158/2326-6066.CIR-24-0591. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for many cancers but have not shown benefit in prostate cancer (PCa). Chronic inflammation contributes to the immunosuppressive prostate tumor microenvironment (TME) and is associated with poor response to ICIs. The primary source … Read more

Cancer Immunol Res. 2025 Feb 12. doi: 10.1158/2326-6066.CIR-24-0335. Online ahead of print. ABSTRACT Traditional anti-cancer therapies induce tumor cell death and subsequent release of Damage Associated Molecular Patterns (DAMPs) that activate the innate inflammatory response. Paradoxically, after treatment, macrophages often adopt a pro-wound healing, rather than pro-inflammatory, phenotype and contribute to cancer progression. We found … Read more

Cancer Immunol Res. 2025 Feb 11. doi: 10.1158/2326-6066.CIR-24-0513. Online ahead of print. ABSTRACT Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such … Read more

Cancer Immunol Res. 2025 Feb 7. doi: 10.1158/2326-6066.CIR-24-0103. Online ahead of print. ABSTRACT The tumor microenvironment (TME) in solid tumors contains myeloid cells that modulate local immune activity. STING signaling activation in these myeloid cells enhances local type I interferon (IFN) production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid … Read more

Cancer Immunol Res. 2025 Feb 3;13(2):161. doi: 10.1158/2326-6066.CIR-13-2-WWR. NO ABSTRACT PMID:39895312 | DOI:10.1158/2326-6066.CIR-13-2-WWR

Cancer Immunol Res. 2025 Jan 31. doi: 10.1158/2326-6066.CIR-24-0979. Online ahead of print. ABSTRACT Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy, and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis … Read more

Cancer Immunol Res. 2025 Jan 29. doi: 10.1158/2326-6066.CIR-23-0903. Online ahead of print. ABSTRACT Radio-immunotherapy has antitumor activity but also causes toxicity, which limits its clinical application. JS-201 is a dual antibody targeting PD-1 and TGF-β signaling. We investigated the antitumour effect of JS-201 combined with radiotherapy and the effect on radiation-induced lung injury (RILI). Different … Read more

Cancer Immunol Res. 2025 Jan 24. doi: 10.1158/2326-6066.CIR-24-0649. Online ahead of print. ABSTRACT Testing for PD-L1 expression by immunohistochemistry (IHC) is used to predict immune checkpoint blockade (ICB) benefit but has performed inconsistently in urothelial cancer (UC) clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on UC samples … Read more

Cancer Immunol Res. 2025 Jan 16. doi: 10.1158/2326-6066.CIR-24-0259. Online ahead of print. ABSTRACT Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that employs a guide … Read more

Cancer Immunol Res. 2025 Jan 14. doi: 10.1158/2326-6066.CIR-23-0999. Online ahead of print. ABSTRACT Based on the notion that hypomorphic germline genetic variants are linked to autoimmune diseases, we reasoned that novel targets for cancer immunotherapy might be identified through germline variants associated with greater T-cell infiltration into tumors. Here, we report that while investigating germline … Read more

Cancer Immunol Res. 2025 Jan 13. doi: 10.1158/2326-6066.CIR-24-1003. Online ahead of print. ABSTRACT Tumor-specific HLA class I expression is required for cytotoxic T-cell elimination of cancer cells expressing tumor-associated or neo-antigens. Cancers downregulate antigen presentation to avoid adaptive immunity. The highly polymorphic nature of the genes encoding these proteins, coupled with quaternary-structure changes after formalin … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-24-0857. Online ahead of print. ABSTRACT T cell-based therapies, including Tumor Infiltrating Lymphocyte Therapy (TIL), T cell receptor engineered T cells (TCR T), and Chimeric Antigen Receptor T cells (CAR T), are powerful therapeutic approaches for cancer treatment. While these therapies are primarily known for their direct cytotoxic … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-23-0563. Online ahead of print. ABSTRACT The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers predict the immune landscape in gastric adenocarcinoma-an aggressive cancer often linked to … Read more

Cancer Immunol Res. 2025 Jan 9:OF1-OF19. doi: 10.1158/2326-6066.CIR-23-1011. Online ahead of print. ABSTRACT Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model … Read more

Cancer Immunol Res. 2025 Jan 9;13(1):7. doi: 10.1158/2326-6066.CIR-13-1-WWR. NO ABSTRACT PMID:39780660 | DOI:10.1158/2326-6066.CIR-13-1-WWR

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0775. Online ahead of print. ABSTRACT Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 … Read more

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0421. Online ahead of print. ABSTRACT Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control of immune responses. The rare cDC1 population is of particular interest because of its remarkable ability to cross-present antigens (Ag) to CD8+ T … Read more

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0445. Online ahead of print. ABSTRACT Anaplastic lymphoma kinase (ALK)-fusion proteins resulting from chromosomal rearrangements are promising targets for cancer immunotherapy. While ALK-specific CD8+ T cells and epitopes presented on MHC class I have been identified in patients with ALK-positive malignancies, little is known about ALK-specific CD4+ T … Read more

Cancer Immunol Res. 2025 Jan 6:OF1-OF19. doi: 10.1158/2326-6066.CIR-24-0298. Online ahead of print. ABSTRACT Despite advances in cancer immunotherapy, such as targeting the PD-1/PD-L1 axis, a substantial number of patients harbor tumors that are resistant or relapse. Selective engagement of T-cell co-stimulatory molecules with bispecific antibodies may offer novel therapeutic options by enhancing signal 1-driven activation … Read more

Cancer Immunol Res. 2025 Jan 2. doi: 10.1158/2326-6066.CIR-24-0589. Online ahead of print. ABSTRACT Despite the pivotal role of cytotoxic T lymphocytes (CTLs) in anti-tumor immunity, a substantial proportion of CTL-rich hepatocellular carcinoma (HCC) patients experience early relapse or immunotherapy resistance. However, spatial immune variations impacting the heterogeneous clinical outcomes of CTL-rich HCCs remain poorly understood. … Read more

Cancer Immunol Res. 2025 Jan 2. doi: 10.1158/2326-6066.CIR-24-0184. Online ahead of print. ABSTRACT Tumor cell-intrinsic signaling pathways can drastically affect the tumor immune microenvironment, promoting tumor progression and resistance to immunotherapy by excluding immune-cell populations from the tumor. Several tumor cell-intrinsic pathways have been reported to modulate myeloid-cell and T-cell infiltration creating “cold” tumors. However, … Read more

Cancer Immunol Res. 2024 Dec 23. doi: 10.1158/2326-6066.CIR-24-0235. Online ahead of print. ABSTRACT CD8+ T-cell abundance is insufficient to assess antitumor immunity and shows poor performance in predicting breast cancer prognosis and immunotherapy response, presumably owing to the complexity of CD8+ T-cell functionalities. While single-cell RNA sequencing (scRNA-seq) can dissect the multifaceted functions of CD8+ … Read more

Cancer Immunol Res. 2024 Dec 12. doi: 10.1158/2326-6066.CIR-24-0610. Online ahead of print. ABSTRACT Radiotherapy (RT) combined with immune checkpoint inhibitor (ICI) therapy has attracted substantial attention due to its potential to improve outcomes for patients with several types of cancer. However, the optimal administration timepoints and drug combinations remain unclear because the mechanisms underlying RT-induced … Read more

Cancer Immunol Res. 2024 Dec 12. doi: 10.1158/2326-6066.CIR-24-0384. Online ahead of print. ABSTRACT Many tumor-specific monoclonal antibody therapies stimulate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells through FcγRIIIa (CD16). The efficacy of these ADCC-based immunotherapies is potentiated in patients with the common CD16 polymorphic variant F158-V that increases the binding affinity between the … Read more

Cancer Immunol Res. 2024 Dec 12. doi: 10.1158/2326-6066.CIR-24-0250. Online ahead of print. ABSTRACT The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment (TME) and promotes tumor progression remain unclear. In this study, we investigated the expression and function of complement C5a receptor 1 (C5aR1) in human and … Read more

Cancer Immunol Res. 2024 Dec 11. doi: 10.1158/2326-6066.CIR-24-0299. Online ahead of print. ABSTRACT Tertiary lymphoid structures (TLS) in cancer are considered ectopic hotspots for immune activation that are similar to lymphoid follicles in secondary lymphoid organs (SLO). This study elucidates shared and TLS/SLO-specific features in pancreatic ductal adenocarcinoma (PDAC). TLS abundance was related to superior … Read more

Cancer Immunol Res. 2024 Dec 10. doi: 10.1158/2326-6066.CIR-24-0514. Online ahead of print. ABSTRACT Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II-positive (HLA-II+) endometrial cancer with an inflamed TME using a … Read more

Cancer Immunol Res. 2024 Dec 6. doi: 10.1158/2326-6066.CIR-24-0189. Online ahead of print. ABSTRACT The term cancer immunoediting describes the dual role by which the immune system can suppress and promote tumour growth and is divided into three phases: elimination, equilibrium and escape. The role of NK cells has mainly been attributed to the elimination phase. … Read more

Cancer Immunol Res. 2024 Dec 3;12(12):1661. doi: 10.1158/2326-6066.CIR-12-12-WWR. NO ABSTRACT PMID:39623982 | DOI:10.1158/2326-6066.CIR-12-12-WWR

Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0713. Online ahead of print. ABSTRACT Regulatory T (Treg) cells play key roles in cancer immunity by suppressing a range of antitumor immune responses and contributing to resistance to programmed death (PD)-1 blockade therapy. Given their critical roles in self-tolerance, local control of immunosuppression by Treg cells, such … Read more

Cancer Immunol Res. 2024 Nov 27. doi: 10.1158/2326-6066.CIR-24-0484. Online ahead of print. ABSTRACT The limited infiltration of CD8+ T cells in tumors hampers the effectiveness of T cell-based immunotherapy, yet the mechanisms that limit tumor infiltration by CD8+ T cells remain unclear. Through bulk RNA sequencing of human tumors, we identified a strong correlation between … Read more

Cancer Immunol Res. 2024 Nov 26. doi: 10.1158/2326-6066.CIR-23-0514. Online ahead of print. ABSTRACT Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components … Read more

Cancer Immunol Res. 2024 Nov 25. doi: 10.1158/2326-6066.CIR-24-0245. Online ahead of print. ABSTRACT Pleural mesothelioma (PM) is a fatal disease with limited treatment options. Recently, PM management has improved with the development of immune checkpoint inhibitors (ICIs). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control and patient survival compared with chemotherapy. Unfortunately, … Read more

Cancer Immunol Res. 2024 Nov 21. doi: 10.1158/2326-6066.CIR-24-0124. Online ahead of print. ABSTRACT Approximately 70% of patients receiving immune checkpoint blockade therapies develop treatment resistance. Thus, there is a need for the identification of additional immunotherapeutic targets. CD49a is a membrane protein expressed on NK cells and T cells. In this study, we found that … Read more

Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. ABSTRACT Natural killer (NK) cell tumor infiltration is associated with good prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). NK cells recognize and kill targets by a process called natural cytotoxicity. We hypothesized that promoting an antigen-specific synapse with co-activation may enhance … Read more

Cancer Immunol Res. 2024 Nov 14:OF1. doi: 10.1158/2326-6066.CIR-24-1029. Online ahead of print. NO ABSTRACT PMID:39540853 | DOI:10.1158/2326-6066.CIR-24-1029

Cancer Immunol Res. 2024 Nov 8. doi: 10.1158/2326-6066.CIR-24-0324. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DCs) in liver malignancies. Here, … Read more

Cancer Immunol Res. 2024 Nov 12. doi: 10.1158/2326-6066.CIR-24-0084. Online ahead of print. ABSTRACT Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer with a low rate of response to immunotherapy such as immune checkpoint blockade (ICB) therapy. Here, we report that nucleus accumbens-associated protein 1 (NAC1), a putative driver of EOC, has … Read more

Cancer Immunol Res. 2024 Nov 11. doi: 10.1158/2326-6066.CIR-24-0561. Online ahead of print. ABSTRACT Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma (EGA), but long-term survival remains limited. Herein, we report extended follow-up data from the INTEGA trial (NCT03409848), which investigated the efficacy of the anti-PD-1 nivolumab, trastuzumab, … Read more

Cancer Immunol Res. 2024 Nov 1. doi: 10.1158/2326-6066.CIR-24-0320. Online ahead of print. ABSTRACT Major histocpmpatibilty complex class I (MHC I) antigen presentation allows CD8+ T cells to detect and eliminate cancerous or virally infected cells. The MHC I pathway is not essential for cell growth and viability and consequently cancers and viruses can evade control … Read more

Cancer Immunol Res. 2024 Oct 30:OF1. doi: 10.1158/2326-6066.CIR-24-0925. Online ahead of print. ABSTRACT γδ T cells have recently raised great interest as effector cells in cancer immunotherapy because of their HLA-independent mode of action and their broad tumor reactivity. To translate the application of γδ T cells into clinically effective immunotherapies, specific tumor targeting and/or … Read more

Cancer Immunol Res. 2024 Oct 29. doi: 10.1158/2326-6066.CIR-24-0039. Online ahead of print. ABSTRACT Glutamine is a major energy source for tumor cells and blocking glutamine metabolism is being investigated as a promising strategy for cancer therapy. However, the antitumor effect of glutamine blockade in bladder cancer remains unclear, necessitating further investigation. Here, we demonstrated that … Read more

Cancer Immunol Res. 2024 Oct 21. doi: 10.1158/2326-6066.CIR-24-0051. Online ahead of print. ABSTRACT B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term response has yet to be established. We investigated the feasibility of CBG-002, an … Read more

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0138. Online ahead of print. ABSTRACT The T cell antigen coupler (TAC) is a chimeric receptor that facilitates tumor antigen-specific activation of T cells by co-opting the endogenous T cell receptor complex in the absence of tonic signaling. Previous data demonstrates that TAC affords T cells with the … Read more

Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0416. Online ahead of print. ABSTRACT Resistance to immune checkpoint inhibitors (ICIs) is common, even in tumors with T cell infiltration. We thus investigated consequences of ICI-induced T cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in … Read more

Cancer Immunol Res. 2024 Oct 10. doi: 10.1158/2326-6066.CIR-23-1092. Online ahead of print. ABSTRACT The survival rate of glioma patients has not significantly increased in recent years despite aggressive treatment and advances in immunotherapy. The limited response to treatments is partially attributed to the immunosuppressive tumor microenvironment, where regulatory T cells (Tregs) play a pivotal role … Read more

Cancer Immunol Res. 2024 Oct 8. doi: 10.1158/2326-6066.CIR-23-0639. Online ahead of print. ABSTRACT Neoantigen-targeted therapy holds an array of benefits for cancer immunotherapy, but the identification of peptide targets with tumor rejection capacity remains a limitation. To better define the criteria dictating tumor rejection potential, we examined the capacity of high-magnitude T cell responses induced … Read more

Cancer Immunol Res. 2024 Oct 4. doi: 10.1158/2326-6066.CIR-24-0089. Online ahead of print. ABSTRACT The histone methyltransferase enhancer of zeste homolog 2 (EZH2) plays important roles in T-cell differentiation, proliferation and function. Previous studies have demonstrated that genetic deletion of EZH2 in CD8+ or total T cells impairs their antiviral and antitumor activity, cytokine production and … Read more

Cancer Immunol Res. 2024 Oct 1;12(10):1309. doi: 10.1158/2326-6066.CIR-12-10-WWR. NO ABSTRACT PMID:39350684 | DOI:10.1158/2326-6066.CIR-12-10-WWR

Cancer Immunol Res. 2024 Sep 30. doi: 10.1158/2326-6066.CIR-23-1027. Online ahead of print. ABSTRACT Ovarian cancers and microsatellite stable (MSS) colorectal cancers (CRC) are insensitive to anti-PD1 immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggests a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase 1 dose-escalation study of pembrolizumab … Read more

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-24-0326. Online ahead of print. ABSTRACT During cancer immunosurveillance, dendritic cells (DCs) play a central role in orchestrating T-cell responses against emerging tumors. Capture of miniscule amounts of antigen along with tumor-initiated costimulatory signals can drive maturation of DCs. Expression of CD91 on DCs is essential in cross-priming … Read more

Cancer Immunol Res. 2024 Sep 10. doi: 10.1158/2326-6066.CIR-24-0164. Online ahead of print. ABSTRACT Immune Checkpoint Blockade (ICB) has revolutionized cancer treatment, however the mechanisms determining patient response remain poorly understood. Here, we used machine learning to predict ICB response from germline and somatic biomarkers and interpreted the learned model to uncover putative mechanisms driving superior … Read more

Cancer Immunol Res. 2024 Sep 5. doi: 10.1158/2326-6066.CIR-24-0071. Online ahead of print. ABSTRACT The expression of PD-L1 on tumor cells (TCs) is used as an immunotherapy biomarker in lung cancer, but heterogeneous intratumoral expression is often observed. Using a Digital Spatial Profiling, we performed proteomic and whole-transcriptomic analyses of TCs and immune cells (ICs) in … Read more

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-24-0026. Online ahead of print. ABSTRACT Radiotherapy (RT) triggers an immune response that contributes to anti-tumor effects. Induction of interferon beta (IFN-β) is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFN-β expression in Toll-like receptor-activated myeloid cells. … Read more

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-23-1075. Online ahead of print. ABSTRACT Despite recent advances in immunotherapy with immune checkpoint inhibitors (ICI), many patients with non-small cell lung cancer (NSCLC) fail to respond or develop resistance after an initial response. In situ vaccination (ISV) with engineered viruses has emerged as a promising antigen-agnostic strategy … Read more

Cancer Immunol Res. 2024 Sep 20. doi: 10.1158/2326-6066.CIR-23-0868. Online ahead of print. ABSTRACT Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Butyrophilin subfamily 2 member A1 (BTN2A1) is a surface protein that has recently been shown to bind the Vγ9 chain of the γδ T-cell receptor (TCR) but its precise role in modulating Vγ9Vδ2 … Read more

Cancer Immunol Res. 2024 Sep 16. doi: 10.1158/2326-6066.CIR-24-0037. Online ahead of print. ABSTRACT T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction … Read more

Cancer Immunol Res. 2024 Sep 13:OF1-OF9. doi: 10.1158/2326-6066.CIR-23-0642. Online ahead of print. ABSTRACT Neutrophils are the primary myeloid cells that are recruited to inflamed tissues, and they are key players during colitis, being also present within the tumor microenvironment during the initiation and growth of colon cancer. Neutrophils fundamentally serve to protect the host against … Read more

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-24-0469. Online ahead of print. ABSTRACT Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely associated with tobacco-associated lung adenocarcinoma (LUAD) in a human-relevant mouse model. Furthermore, we demonstrated that the … Read more

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-23-1094. Online ahead of print. ABSTRACT The great success of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest efficacy, but efforts to develop more … Read more

T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction between PD-1+ and PD-1- T cells in terms of clonal overlap. However, CD8+PD-1+ T cells from PB and tumor tissues exhibited tighter clustering based on clone size. Single-cell RNA…

Ferroptosis is an iron-dependent form of cell death that influences cancer immunity. Therapeutic modulation of ferroptosis is considered a potential strategy to enhance the efficacy of other cancer therapies, including immunotherapies such as chimeric antigen receptor (CAR) T cell therapy. In this study, we demonstrated that IFN-κ influenced the induction of ferroptosis. IFN-κ could enhance the sensitivity of tumor cells to ferroptosis induced by the small molecule compound erastin and the…

Local recurrence and distal metastasis negatively impact the survival and quality of life in patients with papillary thyroid cancer (PTC). Therefore, identifying potential biomarkers and therapeutic targets for PTC is clinically crucial. In this study, we performed a multi-omics analysis that identified a subset of CD36+ pro-inflammatory macrophages within the tumor microenvironment of PTC. The recruitment of CD36+ macrophages to pre-malignant regions strongly correlated with unfavorable…

Abnormal metabolism in tumor cells represents a potential target for tumor therapy. In this regard, dietary restriction (DR) or its combination with anticancer drugs is of interest as it can impede the growth of tumor cells. In addition to its effects on tumor cell, DR also plays an extrinsic role in restricting tumor growth by regulating immune cells. Natural killer (NK) cells are innate immune cells involved in tumor immunosurveillance. However, it remains uncertain whether DR can assist NK…